RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus

Glen Rock, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC-BB:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that scientists associated with the Company have published a manuscript that raises the hope of novel treatments for tinnitus, the perception of sound in the absence of external auditory stimulation. Tinnitus is highly prevalent, with 10-15% of the general population worldwide affected, a statistic that can double in the elderly. The disorder can be markedly debilitating and is associated with and likely causal of anxiety, irritability, depression, sleep loss, social isolation, and suicidal ideation. While there are no treatments that demonstrate any robust efficacy, decades old data from pioneers in the field first discussed the impact of loss of neural inhibition in the disease.